DX5057
Asset
Oral small molecule inhibition of DUX4, the transcription factor driving FSHD pathology.
- Stage
- Preclinical
- Modality
- Small molecule
- Target
- DUX4
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Facioscapulohumeral muscular dystrophy
Preclinical, altaytherapeutics.com, 10 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Competitors3
Every asset’s record: target, stage, trials and the evidence behind it.